QUASAR V

A randomised, phase II/III multi-centre vaccine study post adjuvant therapy for colorectal cancer
Chief Investigator: Dr Rachel Midgley
The trial will compare a vaccine (Tro Vax®) with placebo, given to patients following adjuvant therapy for colorectal cancer.

STUDY STATUS

Prospective [Application made for funding]
Target recruitment: 2786 patients

STUDY SCHEMA

AspECT study arms

STUDY OBJECTIVES

Primary:

Secondary:

Oncology Clinical Trials Office (OCTO)

Randomisation Service Mon-Fri 9-5 (UK Time):

UK Tel: 0800 389 1635, UK Fax: 0800 389 1629 (24hrs)
Non UK Tel: +44 (0)1865 617 014, Non UK Fax: +44 (0)1865 617 015 (24hrs)

General Enquiries:

Tel: +44 (0)1865 617 000, Fax: +44 (0)1865 617 010

Email: enquiries@octo-oxford.org.ukWebsite: www.octo-oxford.org.uk
Header

University of Oxford Crest

Department of
Clinical Pharmacology